查詢結果分析
來源資料
相關文獻
- Triple Therapy of Helicobacter Pylori Infection with Bismuth Salt, Metronidazole, and Tetracycline
- Lansoprazole三合療法與Bismuth三合療法對國人幽門曲狀桿菌陽性消化性潰瘍療效之比較
- 一週四合療法對治療國人幽門曲狀桿菌感染之療效
- Campylobacter Pylori, Gastritis and Peptic Ulceration
- Clarithromycin in the Combination Therapy for the Eradication of Helicobacter Pyloriin Peptic Ulcer Disease
- Omeprazole Plus Amoxicillin Versus Triple Therapy Eradicates Helicobacter Pylori in the Chinese with Peptic Ulcer Disease
- Helicobacter Pylori Infection and Risk of Peptic Ulcer Among Cirrhotic Patients
- 幽門螺旋桿菌之消除與消化性潰瘍之治療
- Randomized Controlled Trial of Omeprazole Plus Amoxicillin vs. Triple Therapy for Eradication of Helicobacter pylori
- 消化性潰瘍的元兇--幽門螺旋桿菌
頁籤選單縮合
題 名 | Triple Therapy of Helicobacter Pylori Infection with Bismuth Salt, Metronidazole, and Tetracycline=以三合療法治幽門曲狀桿菌 |
---|---|
作 者 | 林憲宏; 黃呂津; 姚介和; 趙哲仁; | 書刊名 | 慈濟醫學 |
卷 期 | 6:1 1994.03[民83.03] |
頁 次 | 頁1-5 |
分類號 | 415.526 |
關鍵詞 | 消化性潰瘍; 幽門曲狀桿菌; 三合療法; Helicobacter pylor; Peptic ulcer; Triple therapy; Rapid urease test; |
語 文 | 英文(English) |
中文摘要 | 幽門曲狀桿菌感染與消化性潰瘍有密切關係,國外之研究顯示消除幽門 曲狀桿菌可以防止消化性潰瘍之復發。抗生素之濫用在台灣常被詬病,為了評估 台灣東部花蓮地區幽門曲狀桿菌可能之抗藥性,我們以三合療法(鉍鹽、四環素、 及metronidazole)對幽門曲狀桿菌感染伴有消化性潰瘍者作治療試驗。計有63例消 化性潰瘍者(8例胃、51例十二指腸、4例胃及十二指腸)接受第2次內規鏡檢查,所 有患者均以第二型組織胺受體拮抗劑治療消化性潰瘍,其中36倒立接受三合療 法。治療組只有2例因副作用無法完成療程,合作度為94.4。於3個月內評估時, 治療組之幽門曲狀桿菌消除率為90.0(19/20),3至18個月的評估,消除率為 78.6(11/14),而對照組所有病例之幽門曲狀桿菌均持續存在。潰瘍之癒合率在治 療組與對照組並無顯著差別(19/20對2/3,或95.0對66.7),潰瘍癒合率與幽門曲狀 桿菌的消除與否亦無顯著關聯性(17/l8對4/5,或94.4對80.0)。潰瘍之復發率則在對 照組有顯著的較高(18/24對2/14,或75.0對14.3,P<0.001),幽門曲狀桿菌未消除者 之潰瘍復發率亦顯著的較高(16/24對1/11,66.7對9.1,P<0.005)。本研究結果顯示,治 療並消除幽門曲狀桿菌的確可以減少消化性潰瘍之復發;在花蓮地區,幽門曲狀 桿菌之抗藥性並不常見。對於消化性潰瘍且有幽門曲狀桿菌感染者,應給予三合 療法治療。(慈濟醫學1994;6:1-5) |
英文摘要 | Helicobacter pylori infection of stomach is closely associated with peptic ulceration. It is nowfairly established that eradication of H pylori prevents recurrence of peptic ulcer. Antibioticsoveruse has been a problem in Taiwan. To evaluate the rate of primary drug resistance of H pyloriin Hualien, eastern Taiwan, we performed a nonrandomized study of triple therapy of H pyloriwith tetracycline, metronidazole, and bismuth salt. A total of 63 patients with peptic ulcer (8gastric, 51 duodenal, and 4 gastric and duodenal ulcers) and H pylori infection were enrolled.Thirty six patients received triple therapy and 27 did not. Two patients failed to complete the tripletherapy due to side effects (a compliance rate of 94.4). When evaluated within 3 months, H pyloriwas eradicated in 90 (19/20) of patients treated. The eradication rate was 78.6 (11/14) whenevaluated 3 to 18 months later. None of the patients in the control group had their H pylori eradicated. The ulcer healing rates were not significantly different between patients treated or nottreated for H pylori (19/20 vs 2/3, or 95.0 vs 66.7), nor between patients with or withouteradication ofH pylori (17/18 vs 4/5, or 94.4 vs 80.0). The ulcer relapse rate was significantlyhigher in the control group (18/24 vs 2/14, or 75.0 vs 14.3, P<0.001), and in patients withpersistant H pylori infection (16/24 vs 1/11, or 66.7 vs 9.1, P<0.005). The results confirm thefact that treatment and eradication ofH pylori reduce ulcer recurrence. Primary drug resistanceofH pylori seems to be uncommon in Hualien. (Tzu-Chi Med J 1994; 6: 1-5) |
本系統中英文摘要資訊取自各篇刊載內容。